The Evolution of Endocardial Thrombosis in Heart Failure
心力衰竭心内膜血栓形成的演变
基本信息
- 批准号:7465370
- 负责人:
- 金额:$ 12.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-08-01 至 2009-05-31
- 项目状态:已结题
- 来源:
- 关键词:Adenovirus VectorAnticoagulantsBiologyCardiacCardiovascular systemCellsChronicCoagulation ProcessCommitComplicationConditionDataDevelopmentDilated CardiomyopathyDiseaseDown-RegulationEndocardiumEndotheliumEquilibriumEvolutionFailureGene DeliveryGene ExpressionGoalsHeartHeart failureHomeostasisIn VitroInflammatoryLaboratoriesLeadLinkMechanical StressModelingMolecularMorbidity - disease rateMusNatureOryctolagus cuniculusPathway interactionsPatientsPhysiciansPlasmaPlayPrincipal InvestigatorPropertyProtein CProteinsResearchResearch PersonnelResearch Project GrantsRiskRoleScientistSignal TransductionSourceStimulusStressSurfaceSystemTFPITherapeuticThrombinThrombomodulinThromboplastinThrombosisTranslational ResearchUnited StatesVascular EndotheliumWorkabstractingactivated Protein Cin vivoin vivo Modelindexingmortalitypressureprogramsreceptorresearch studyrestorationskills
项目摘要
DESCRIPTION (provided by applicant):
This K08 application focuses on the thrombosis which occurs as a common and severe complication in chronic heart failure (CHF), a major source of morbidity and mortality in the U.S. Recent evidence has linked CHF with a hypercoagulable state as demonstrated by elevated indices of thrombin and tissue factor (TF) activation. Both thrombin and TF play a critical role in the formation of clot and thrombotic complications on the endothelial surface, however, their role in thrombosis in CHF is currently unclear. The Principal Investigator has proposed a comprehensive five-year research program that will focus on the procoagulant and anticoagulant molecules on the endocardium in the prothrombotic state of chronic heart failure (CHF). This proposal builds upon exciting preliminary data generated in our laboratory which has led to a working hypothesis that the biophysical and inflammatory conditions in CHF lead to a loss of thromboresistance in the failing heart. We will examine whether the condition of heart failure alters endocardia! anticoagulant-procoagulant homeostasis such that these changes are associated with increased thrombogenicity. Specific Aim #1 will provide careful in vivo analysis of anticoagulant and procoagulant molecules on the endocardium and the functional consequences of altered anticoagulantprocoagulant homeostasis. Specific Aim #2 will examine in vitro underlying molecular mechanisms of altered homeostasis determined in inflammatory- and mechanically-stressed murine endocardium. Finally, Specific Aim #3 will explore in vivo strategies to restore homeostasis on the endocardium using adenoviral gene delivery and exogenous activated protein C. In summary, our studies will elucidate the critical role of the endocardium in maintaining anticoagulant-procoagulant homeostasis and how CHF alters this balance. This research project will synthesize experiments already familiar to the Principal Investigator and his sponsor's laboratory as well as new experiments and skills that are vital to the Pi's development as a physician scientist. These results may lead to a shift in our current understanding of thrombosis in CHF and potentially lead to strategies which would directly impact patients with CHF at risk for thrombosis. Chronic heart failure is an extremely common disease in the United States with over 5 million cases. Thromboembolic disease is a significant problem in patients with CHF. Elucidating the mechanisms underlying the procoagulant nature of CHF could greatly reduce the associated morbidity and mortality.
(End of Abstract)
描述(由申请人提供):
K08的应用重点是血栓形成,这是慢性心力衰竭(CHF)的一种常见和严重的并发症,慢性心力衰竭是美国发病率和死亡率的主要来源。最近的证据表明,CHF与高凝状态有关,凝血酶和组织因子(TF)激活指数的升高证明了这一点。凝血酶和转铁蛋白在血管内皮细胞表面血栓形成和血栓并发症的形成中起重要作用,但它们在充血性心力衰竭血栓形成中的作用目前尚不清楚。首席调查员提出了一项全面的五年研究计划,重点是慢性心力衰竭(CHF)血栓前状态下心内膜上的促凝剂和抗凝血剂分子。这一建议建立在我们实验室产生的令人兴奋的初步数据的基础上,这些数据导致了一个工作假设,即CHF中的生物物理和炎症条件导致衰竭心脏的血栓抵抗丧失。我们将研究心力衰竭的状况是否会改变心内膜!抗凝剂-促凝剂的动态平衡,因此这些变化与血栓形成能力的增加有关。具体目标#1将提供对心内膜上抗凝剂和促凝剂分子的体内仔细分析,以及抗凝剂促凝血剂动态平衡改变的功能后果。具体目标#2将在体外研究炎症和机械应激小鼠心内膜中确定的动态平衡改变的潜在分子机制。最后,具体目标#3将探索在体策略,使用腺病毒基因传递和外源激活蛋白C来恢复心内膜的动态平衡。综上所述,我们的研究将阐明心内膜在维持抗凝-促凝剂动态平衡中的关键作用,以及CHF如何改变这种平衡。这项研究项目将综合首席调查员和他的赞助商实验室已经熟悉的实验,以及对PI作为内科科学家的发展至关重要的新实验和技能。这些结果可能会改变我们目前对CHF血栓形成的理解,并可能导致直接影响有血栓形成风险的CHF患者的策略。慢性心力衰竭在美国是一种非常常见的疾病,有超过500万例。血栓栓塞症是充血性心力衰竭患者的一个重要问题。阐明充血性心力衰竭促凝血特性的潜在机制可以大大降低相关的发病率和死亡率。
(摘要结束)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANTONY Y KIM其他文献
ANTONY Y KIM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANTONY Y KIM', 18)}}的其他基金
The Evolution of Endocardial Thrombosis in Heart Failure
心力衰竭心内膜血栓形成的演变
- 批准号:
7629686 - 财政年份:2007
- 资助金额:
$ 12.44万 - 项目类别:
The Evolution of Endocardial Thrombosis in Heart Failure
心力衰竭心内膜血栓形成的演变
- 批准号:
7249876 - 财政年份:2007
- 资助金额:
$ 12.44万 - 项目类别:
The Evolution of Endocardial Thrombosis in Heart Failure
心力衰竭心内膜血栓形成的演变
- 批准号:
8075478 - 财政年份:2007
- 资助金额:
$ 12.44万 - 项目类别:
The Evolution of Endocardial Thrombosis in Heart Failure
心力衰竭心内膜血栓形成的演变
- 批准号:
7884389 - 财政年份:2007
- 资助金额:
$ 12.44万 - 项目类别:
相似海外基金
EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort
EPIPHANy(癌症患者抗凝药理相互作用的评估)计划 - 前列腺癌队列
- 批准号:
479295 - 财政年份:2023
- 资助金额:
$ 12.44万 - 项目类别:
Operating Grants
Inhibitors of Human Factor XIIIa as New Anticoagulants
人类因子 XIIIa 抑制剂作为新型抗凝剂
- 批准号:
10629057 - 财政年份:2023
- 资助金额:
$ 12.44万 - 项目类别:
Establishment of comprehensive monitoring of direct oral anticoagulants (DOACs) for clinical application
建立临床应用直接口服抗凝剂(DOAC)综合监测体系
- 批准号:
23K06906 - 财政年份:2023
- 资助金额:
$ 12.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Interactions of Enzyme-Inducing Antiepileptic Drugs with Direct-Acting Oral Anticoagulants: Risk of Thromboembolic Events
酶诱导抗癫痫药物与直接作用口服抗凝剂的相互作用:血栓栓塞事件的风险
- 批准号:
10605482 - 财政年份:2023
- 资助金额:
$ 12.44万 - 项目类别:
The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation
口服抗凝药对肝硬化合并心房颤动患者的有效性和安全性比较
- 批准号:
10559071 - 财政年份:2023
- 资助金额:
$ 12.44万 - 项目类别:
Search for indicators of blood levels of directly inhibitory oral anticoagulants in coagulation tests using artificial intelligence
使用人工智能在凝血测试中搜索直接抑制性口服抗凝剂的血液水平指标
- 批准号:
22K07388 - 财政年份:2022
- 资助金额:
$ 12.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Bleeding on Direct Oral Anticoagulants: Identification of Genetic Risk Factors and a Polygenic Predictive Score in Patients with Atrial Fibrillation
直接口服抗凝剂导致的出血:房颤患者遗传风险因素的鉴定和多基因预测评分
- 批准号:
10536789 - 财政年份:2022
- 资助金额:
$ 12.44万 - 项目类别:
Study on proper use of oral anticoagulants combined with 5-fluorouracil
口服抗凝药联合5-氟尿嘧啶正确使用研究
- 批准号:
22K06743 - 财政年份:2022
- 资助金额:
$ 12.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Benchmarking a point-of-care test kit for detection of direct-oral anticoagulants
用于检测直接口服抗凝剂的即时检测试剂盒的基准测试
- 批准号:
461790 - 财政年份:2022
- 资助金额:
$ 12.44万 - 项目类别:
Operating Grants
Direct oral anticoagulants and the risk of colorectal and pancreatic cancers: a population-based cohort study.
直接口服抗凝剂与结直肠癌和胰腺癌的风险:一项基于人群的队列研究。
- 批准号:
474475 - 财政年份:2022
- 资助金额:
$ 12.44万 - 项目类别:
Studentship Programs














{{item.name}}会员




